Sabarubicin - Menarini Pharmaceuticals

Drug Profile

Sabarubicin - Menarini Pharmaceuticals

Alternative Names: BMS 195615; MEN-10755

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Menarini
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action Apoptosis stimulants; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 06 Feb 2018 Sabarubicin is still in clinical development for Small cell lung cancer (Menarini Pharmaceuticals website, February 2018)
  • 09 Sep 2015 No recent reports on development was identified - Phase-II for Solid tumours in Europe (IV)
  • 03 Jun 2008 Final efficacy and adverse event data from a phase II trial in Small cell lung cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top